All articles
Filter by theme · newest first
-
The Money in Chinese Medical Aesthetics Is Not as Easy as It Looks
China’s addressable medical-aesthetics market is far smaller than a population of 1.4 billion implies. This piece re-examines where the real boundary sits, through four lenses: how penetration is measured, spending power, the reach of falling prices, and value-based pricing.
10 min read -
Capital and Medical Aesthetics: A Game of Valuation, Narrative and Time
I have been vibe coding my way through an analysis of the competitive landscape in medical aesthetics, and it is becoming genuinely hard to define what a pure upstream medical-aesthetics company even is any more.
25 min read -
A Credible Market Analysis Is Harder Than It Looks
Bombarded by market noise every day, and hearing the competitive pressure in every conversation with a business head, I always start with the numbers — industry data, competitor data, and the company’s own.
6 min read -
Upstream Medical Aesthetics, FY2025: A Head-to-Head Review of 12 Listed Companies
The end of April is the annual-report deadline. By then — Hong Kong-listed companies aside, where quarterlies are not mandatory — many A-share players have already published Q1 as well.
14 min read -
Going Global Is Quietly Deciding Which Medical-Aesthetics Companies Have a Future
Rather than the endless churn of the domestic market, I have always preferred to look at what is different in global markets and where the trends are pointing.
9 min read -
The Industry’s Herd Moment: From a Half-Empty Conference Hall to the Distance We Keep from Independent Thought
Late one night a friend forwarded me the video of the half-empty hall at the MWS congress. One look at the engagement numbers and the question was obvious: what do you make of it? So let me ride the trend for once, and ask the larger question — why is our industry so easily carried along by a single clip or a single remark?
10 min read -
AI Commercialisation in Chinese Medical Aesthetics Is, Right Now, a Media Carnival
As AI dominates more and more of the conversation, the industry looks like it is standing at the threshold of a productivity revolution. Today I want to make an argument that may not win me friends: AI commercialisation in Chinese medical aesthetics is a self-media carnival. At the end of the piece I invited Claude, currently the strongest AI tool available, to respond to my case.
12 min read -
The Quiet Q1 of 2026: What Is Behind It, and Where It Points
2025 was busy beyond my ability to describe it. Fifty-two Class III registration certificates were granted in a single year, covering hyaluronic acid, botulinum toxin, collagen, PLLA, PCL, agarose, calcium hydroxylapatite and energy-based devices — almost every category launching at once.
9 min read -
New Brands Entering Medical Aesthetics: Don’t Panic — Go Boldly
Over the past six months I have met a lot of new brands that have just received their registration certificate or are preparing to launch: small innovator companies entering on a single product with a few funding rounds behind them, and listed companies and medical-device groups standing up a new medical-aesthetics division.
11 min read -
A Cold Shower: AI Literacy Will Be the Cut Line in Medical-Aesthetics Marketing
Written from the perspective of a heavy user — more than RMB 2,000 a month on AI, well over a billion tokens across 2025. It reflects where things stand today; next month a new capability may change the picture again.
7 min read -
The Chinese DNA of an “American” Botulinum Toxin Company: What Revelyx’s Model Teaches About Escaping the Domestic Grind
With the approval of Imeik’s Hutox, seven products are now crowded into the same ring — from Botox to Hengli, from Xeomin to Letybo, from Meditoxin to Daxxify. Yet the protagonist of this piece is not Imeik.
7 min read -
Filter Bubbles Are Flattening People and Brands Alike
I have realised I can no longer concentrate on reading for any length of time. To finish a few good books I ended up learning audiobook production and converting them to audio — and only just got through them that way.
6 min read -
Don’t Let “Old Guard Thinking” Define the Age Boundaries of Management
The nineties-born peers around me have replaced “boss” and “executive” with a sardonic vocabulary of their own. Meanwhile, on the industry’s main stage, the veterans born in the sixties and seventies still hold forth — bathed in the glow of past achievement, still cast as the protagonists.
13 min read -
Global Energy-Based Devices in 2025: An Annual Review
In 2025, energy-based devices (EBD) remained one of the most foundational — and most genuinely productive — layers of the global non-surgical aesthetics system.
6 min read -
The Upstream Elimination Race Is Not About Price. It Is About Judgement
This industry’s story has moved on from opportunism and window-of-opportunity gains into an era of collapsing trust, a broken talent pipeline, rampant short-termism and open price wars.
8 min read -
Naming a Medical-Aesthetics Product Is Not Mysticism. It Is a Discipline
From hyaluronic acid to collagen, from regenerative materials to biosynthetics — hundreds of products have launched, yet their names cluster around a handful of the same syllables: zhen, li, yan, su, ai, ti.
8 min read -
Why Medical Aesthetics Is Not Actually as Competitive as It Looks
Recently an upstream manager I admire — serious, grounded — left the industry. Once it was confirmed, what I felt was more complicated than the usual understanding and regret: relief, release, even a little envy. Envy of her resolve, and of her luck.
9 min read -
Three Ways to Avoid the Blind Spots in Medical-Aesthetics Sales Bonus Design
With so many products launching this year, the industry’s sales roles have cycled through almost a full rotation again.
9 min read -
Regional Marketing: The Department Medical-Aesthetics Companies Should Abolish First
A few days ago a friend at a high-end clinic group came to me exasperated: she genuinely cannot understand why a “regional marketing department” exists in this industry at all.
9 min read -
Free-Riding Has Become the Norm: A Systemic Collapse of the Value Chain
Look closely at the commercial logic of medical aesthetics and an uncomfortable pattern emerges: from upstream suppliers to end consumers, from platforms to investors, the entire chain is caught in an invisible war of value extraction. This is not a moral failure of any one group. It is the systemic imbalance of an industry in rapid expansion.
9 min read -
Brand Strategy in Medical Aesthetics: Original Intent Against Commercial Reality
As undifferentiated products flood the market, clinics and distributors are no longer greeting new launches with the old enthusiasm — they are waiting. Waiting on clinical feedback, waiting on where prices settle, and waiting to see whether the brand’s voice in the market can stand out enough to actually help the front line sell.
9 min read -
What It Is Really Like to Work in Medical Aesthetics: The Survey
Last time we published “Working Upstream in Medical Aesthetics: The Complaints”. In the weeks since, both online and off, we have had a great deal of feedback and recognition from readers.
5 min read -
“General Manager Thinking” Is Destroying Small Medical-Aesthetics Companies
Many medical-aesthetics companies start with a single product or a single business line. Facing an unfamiliar category and a complex market, a lot of founders choose to run product development, registration and manufacturing themselves, and hire one “general manager” to own everything commercial — sales, marketing, brand, social, medical affairs and the rest.
8 min read -
Working Upstream in Medical Aesthetics: The Complaints
Whatever your role in this industry, work throws up moments worth complaining about. Some of those complaints turn out to be the main reason people leave.
6 min read -
Small Dose, Big Calculation: Psychological Price Cuts in Medical Aesthetics
Everyone says the PLLA category is grinding toward a price cut, yet each player is still working hard to differentiate on its own strengths: some run product bundles off channel advantage, some polish treatment packaging and internal training, some throw the OEM doors open to grow the whole pie first.
8 min read -
Everyone’s Doing OEM Now? The Business Logic Behind White-Label Medical Aesthetics
From hyaluronic acid to collagen to regenerative microspheres, more and more upstream manufacturers are entering the white-label business. Unlike traditional cosmetics OEM, the medical-aesthetics version behaves much more like tightly regulated medical-device manufacturing.
7 min read -
The Puzzle of a Medical-Aesthetics Brand’s First Impression
The industry has grown fast and brands have sprung up everywhere, each with its own commercial strategy — some carrying a brand across borders and economic cycles, some opening the market fast on margin and channel.
9 min read -
Hearing What the Numbers Say: Data Analysis in Medical Aesthetics, Reality and Possibility
As everyone knows, plenty of upstream companies require daily, weekly and monthly reports from every employee, on top of sell-through, sales performance and marketing spend. Every day seems to be about product, cost, channel, clinics and targets. Add a simple chart deck at intervals and a summary, and on the surface it looks like data analysis. In practice…
6 min read -
The Pricing Myths of Medical-Aesthetics Products
Several new products are about to launch, and multiple versions of their pricing strategy are already circulating. I hear brands have spent days behind closed doors searching for the one “right price”.
13 min read -
The Fall and Rebuilding of the Upstream Marketing Department
Compared with the years when a registration certificate was a trump card, 2025 has brought a near-weekly drumbeat of Class III approvals across treatment categories and new materials. On the other side: shrinking end-consumer demand, clinic closures, less footfall and lower average tickets.
10 min read -
How Upstream Medical Affairs Can Actually Enable Sales
Now that compliant products are being approved in volume, medical affairs is no longer a pure “scientific support” function. A strong medical affairs team should be a core engine of commercial growth. This piece works through the levels medical affairs operates at, and how to maximise market impact on a limited budget.
9 min read
No articles match the selected themes.
Content, copyright and author
About the content
These pieces are based on public information, industry research and first-hand observation, and represent independent analysis only. Examples are used to discuss industry patterns and do not refer to, or imply anything about, any specific brand, company or individual.
Copyright
Original work by Giselle · Aesthetic Reflections. Please credit the author and source when quoting; for full reproduction, contact us for permission.
About the author
A long-running focus on upstream medical aesthetics: market trends, commercial management, brand development, organisation building, professional education and data analysis.